CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Artemis Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Artemis Therapeutics Inc
18 E 16th St
Phone: (646) 233-1454p:646 233-1454 NEW YORK, NY  10003-3111  United States Ticker: ATMSATMS

Business Summary
Artemis Therapeutics, Inc., formerly New York Global Innovations Inc., seeks to offer alternatives to allergy medications. The Company provides various dietary and lifestyle guidelines, and also offers Lucidia and approximately six Chinese herb support formulas for purchase or prescription filling. The Company offers Artemis Allergy Relief Program, which is an educational resource center for health care practitioners, patients, and anyone suffering from seasonal, environmental or pet allergies. The program is a natural approach to allergy treatment or can be used alongside various therapies. The program provides various tools and natural medicinals to cultivate health and mitigate allergy symptoms. Artemis Allergy Treatment Program is intended for people suffering from seasonal allergies or yearlong allergies to pollens, animals, mold, dust, grasses, trees and hay fever.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
IRA CQ
Score
Moody's
Rating
Fitch
Rating
DBRS
Rating
Morningstar
Rating
-Yes-------

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/201912/31/2018YesYes---

Industries
SIC Code Description
6726 Unit investment trusts, face-amount certificate offices

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chief Executive Officer Brian M.Culley 48 10/26/2017 8/18/2017
Chief Financial Officer ChananMorris 50 9/1/2014 9/1/2014
Director; Chief Executive Officer of Artemis Pharma, Inc. IsraelAlfassi 48 8/23/2016 8/23/2016
Chief Scientific Officer DanaWolf 59 8/23/2016 8/23/2016

Business Names
Business Name
ARTEMIS THERAPEUTICS INC.
ATMS
INKS
8 additional Business Names available in full report.

General Information
Number of Employees: 13 (As of 12/31/2011)
Outstanding Shares: 5,153,461 (As of 9/30/2019)
Shareholders: 72
Stock Exchange: OTC
Federal Tax Id: 841417774
Fax Number: (302) 674-5266


Copyright © 2019 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, December 12, 2019